A Phase 1/2 interventional study of [F-18]PBR06 and [C-11]Methylreboxetine in Multiple Sclerosis, sponsored by Brigham and Women's Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Brigham and Women's Hospital · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Multiple Sclerosis by Brigham and Women's Hospital — 4 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis · Brigham and Women's Hospital.
Among the 15 studies in Multiple Sclerosis by Brigham and Women's Hospital, this one is one of 2 that started in 2020, is one of 4 in phase 1/2, and was the 8th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →4 of the 15 studies in Multiple Sclerosis by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18–70 · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 18–60 · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 18–60 · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 18–85 · Healthy volunteers
By country, each count listing its studies:
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2015; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 30 across the 9 interventional studies, 160 across the 6 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
2 of the studies in Multiple Sclerosis by Brigham and Women's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03207464Brigham and Women's HospitalMolecular Imaging of NET Using [C-11]MRB-PET in MS | 2026-12-31 |
| NCT04634994Brigham and Women's HospitalAssessment of Synaptic Density in MS | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Multiple Sclerosis by Brigham and Women's Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and [C-11]MRB.
Specific Aims:
Specific Aim 1: To determine the relationship of cerebral microglial activation, as assessed by [F-18]PBR06 PET, with MS-related fatigue.
Specific Aim 2: To determine the relationship of norepinephrine transporter (NET) binding, as assessed by [C-11]MRB PET, with MS-related fatigue.
Specific Aim 3: To determine the relationship of microglial activation and NET binding, with grey matter pathology (lesion load and brain atrophy) assessed using 7T MRI, and evaluate their independent contribution in development of MS-related fatigue.
Design: This is a single center, cross-sectional study of patients with multiple sclerosis, who will each, undergo both, [C-11]MRB-PET (norepinephrine transporter binding) and [F-18]PBR06-PET (microglial activation), in addition to 7 Tesla brain MRIs. Patients will also undergo cross-sectional estimations of blood markers.
Genotype Testing:
Blood sample drawn on the initial screening visit will be used to obtain genomic DNA for genotyping for polymorphism within the TSPO gene on chromosome 22q13.2, using a Taqman assay. High affinity and medium affinity binders will be included while the low affinity binders will be excluded from the study.
PET Scanning:
During the PET scan visits, all women subjects of child bearing age will undergo a stat quantitative serum hCG pregnancy test and only women with a negative test will undergo the radiopharmaceutical injection. The radiotracers will be produced using standardized procedures. At the time of imaging, the subjects will be positioned in the gantry of a high-resolution PET/CT camera. Head alignment will be made, relative to the canthomeatal line, using projected laser lines whose positions are known with respect to the slice positions of the scanner. A head support apparatus will be used to minimize head motion.Dynamic data over 120 minutes for PET quantification will be acquired, according to previously described methods for both tracers.
MRI Scanning:
High resolution MRI scanning will be performed using the 7T Siemens MAGNETOM Terra MRI unit at Brigham \& Women's Hospital (BWH).
Serum assays:
Serum measurements for inflammatory markers and relevant neurochemicals will be performed according to established procedures.
Clinical Data
The following non-imaging, clinical data will be obtained:
Modified fatigue Impact Scale (MFIS) Fatigue Severity Status Scale (FSSS) Expanded Disability Status Scale (EDSS) Timed 25-feet walk (T25W) MS Functional Composite (MSFC) Symbol digit modalities test (SDMT) MSQOL-54 scale (QOL) Pittsburgh Sleep Quality Index (PSQI) Beck's Depression Inventory (BDI) Center for Epidemiological Studies-Depression Scale (CES-D) Hospital Anxiety and Depression Scale (HADS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing-remitting multiple sclerosis and 6 with secondary progressive multiple sclerosis).
Drug: [F-18]PBR06 · Drug: [C-11]Methylreboxetine
PET radiopharmaceutical. Subjects will undergo \[F-18\]PBR06-PET (microglial activation).
Also known as: [18F]PBR06
PET radiopharmaceutical. Subjects will undergo \[C-11\]MRB-PET (norepinephrine transporter binding).
Also known as: [C-11]MRB
Standardized Uptake Value Ratio (SUVR)
PET outcome measure for \[F-18\]PBR06 radioligand used to quantify microglial activation.
Time frame: Baseline
Area Under the Curve Ratio (AUCR)
PET outcome measure for \[C-11\]MeNer radioligand used to quantify norepinephrine transporter binding in brain regions of interest (e.g, putaminal, pallidal, and white matter).
Time frame: Baseline
Correlations Between Modified Fatigue Impact Scale (MFIS) and PET Outcome Measures
MFIS is a fatigue rating scale. Scores range from 0-84. Higher values indicate worse fatigue.
Time frame: Baseline
Correlations Between Expanded Disability Status Scale (EDSS) and PET Outcome Measures
EDSS is a disability rating scale. Scores range from 0-10. Higher values indicate worse clinical function.
Time frame: Baseline
| Milestone | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Started | 14 |
| Completed | 10 |
| Not completed | 4 |
PET outcome measure for \[F-18\]PBR06 radioligand used to quantify microglial activation.
| SUVR | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Standardized Uptake Value Ratio (SUVR) | 0.78 ± 0.06 |
PET outcome measure for \[C-11\]MeNer radioligand used to quantify norepinephrine transporter binding in brain regions of interest (e.g, putaminal, pallidal, and white matter).
| AUCR | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| AUCR - Putamen/Occipital Lobe | 1.01 ± 0.05 |
| AUCR - Pallidum/Occipital Lobe | 0.84 ± 0.09 |
MFIS is a fatigue rating scale. Scores range from 0-84. Higher values indicate worse fatigue.
| Correlation Coefficient | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Correlation between SUVR and MFIS | 0.65 |
| Correlation between Putamen/Occipital Lobe AUCR and MFIS | 0.46 |
| Correlation between Pallidum/Occipital Lobe AUCR and MFIS | 0.71 |
EDSS is a disability rating scale. Scores range from 0-10. Higher values indicate worse clinical function.
| Correlation Coefficient | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Correlation between SUVR and EDSS | 0.74 |
| Correlation between Putamen/Occipital Lobe AUCR and EDSS | 0.79 |
| Correlation between Pallidum/Occipital Lobe AUCR and EDSS | 0.82 |
Collected over From enrollment to completion of study, an average of 11 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subjects Diagnosed With Multiple Sclerosis | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Event | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Pain/pressure on the back of the head during the MRIMusculoskeletal and connective tissue disorders | 2/10 |
| Dizziness during the MRI.Nervous system disorders | 1/10 |
| Discomfort from the headrest during PET scan.Musculoskeletal and connective tissue disorders | 1/10 |
| Right shoulder pain during the PET scan.Musculoskeletal and connective tissue disorders | 1/10 |
| Age, Continuous(years) | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Mean | 47.00 ± 8.98 |
| Sex: Female, Male(Participants) | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Female | 8 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 10 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| United States | 10 |
| Expanded Disability Status Scale(Score on the EDSS (0-10)) | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Mean | 3.8 ± 2.1 |
| Timed 25-Foot Walk(Time in Seconds) | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Mean | 11.6 ± 14.6 |
| Modified Fatigue Impact Scale(Score on the MFIS (0-84)) | Subjects Diagnosed With Multiple Sclerosis |
|---|---|
| Mean | 34.3 ± 25.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2020 to primary completion in Apr 2021, 13 months.
Results were first posted in Oct 2026, 5 years 6 months after primary completion.
Of 33 phase 1/2 interventional studies under Multiple Sclerosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 89. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PBR-06
Brigham and Women's Hospital →